Cargando…

Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)

The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Renz, Bernhard W., D’Haese, Jan G., Werner, Jens, Westphalen, C. Benedikt, Ilmer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/
https://www.ncbi.nlm.nih.gov/pubmed/29099030
http://dx.doi.org/10.3390/medsci5020014
_version_ 1783270352835575808
author Renz, Bernhard W.
D’Haese, Jan G.
Werner, Jens
Westphalen, C. Benedikt
Ilmer, Matthias
author_facet Renz, Bernhard W.
D’Haese, Jan G.
Werner, Jens
Westphalen, C. Benedikt
Ilmer, Matthias
author_sort Renz, Bernhard W.
collection PubMed
description The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could—at least in part—explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor. At the same time, however, some of these attributes could make CSCs more permissive for novel therapeutic strategies with compounds that are already in clinical use. Most recently, several publications have tried to enlighten the field with the idea of repurposing established drugs for antineoplastic use. As such, recycling drugs could present an intriguing and fast-track method with new therapeutic paradigms in anti-cancer and anti-CSC treatments. Here, we aim to summarize important aspects and novel findings of this emerging field.
format Online
Article
Text
id pubmed-5635789
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56357892017-10-26 Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) Renz, Bernhard W. D’Haese, Jan G. Werner, Jens Westphalen, C. Benedikt Ilmer, Matthias Med Sci (Basel) Review The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could—at least in part—explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor. At the same time, however, some of these attributes could make CSCs more permissive for novel therapeutic strategies with compounds that are already in clinical use. Most recently, several publications have tried to enlighten the field with the idea of repurposing established drugs for antineoplastic use. As such, recycling drugs could present an intriguing and fast-track method with new therapeutic paradigms in anti-cancer and anti-CSC treatments. Here, we aim to summarize important aspects and novel findings of this emerging field. MDPI 2017-06-19 /pmc/articles/PMC5635789/ /pubmed/29099030 http://dx.doi.org/10.3390/medsci5020014 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Renz, Bernhard W.
D’Haese, Jan G.
Werner, Jens
Westphalen, C. Benedikt
Ilmer, Matthias
Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title_full Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title_fullStr Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title_full_unstemmed Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title_short Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
title_sort repurposing established compounds to target pancreatic cancer stem cells (cscs)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/
https://www.ncbi.nlm.nih.gov/pubmed/29099030
http://dx.doi.org/10.3390/medsci5020014
work_keys_str_mv AT renzbernhardw repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs
AT dhaesejang repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs
AT wernerjens repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs
AT westphalencbenedikt repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs
AT ilmermatthias repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs